Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

This publication has 21 references indexed in Scilit:

• A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
  New England Journal of Medicine, 1996
• Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter
  New England Journal of Medicine, 1996
• For Debate: Will we ever know when to treat HIV infection?
  BMJ, 1996
• Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection
  Annals of Internal Medicine, 1996
• The Economic Costs of Caring for People with HIV Infection and AIDS in England and Wales
  PharmacoEconomics, 1996
• Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
  New England Journal of Medicine, 1995
• The Spectrum of Medical Conditions and Symptoms before Acquired Immunodeficiency Syndrome in Homosexual and Bisexual Men Infected with the Human Immunodeficiency Virus
  American Journal of Epidemiology, 1995
• Cost and utilisation of community services for people with HIV infection in London.
  1995
• Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/??l in 5 European Countries
  PharmacoEconomics, 1994
• The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach.
  1991